General - Interventional Oncology
Payments companies reported to CMS as associated with General - Interventional Oncology. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with General - Interventional Oncology, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with General - Interventional Oncology
These are the largest totals companies reported as associated with General - Interventional Oncology. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Siddharth Padia | Los Angeles, CA | Vascular & Interventional Radiology | $9,487.78 |
| Sepideh Gholami | Sacramento, CA | Surgical Oncology | $8,348.17 |
| Robert Lewandowski | Chicago, IL | Vascular & Interventional Radiology | $8,141.92 |
| Jafar Golzarian | Golden Valley, MN | Vascular & Interventional Radiology | $8,037.80 |
| Muneeb Ahmed | Boston, MA | Vascular & Interventional Radiology | $8,027.64 |
| Sean Tutton | San Diego, CA | Vascular & Interventional Radiology | $8,027.63 |
| William Rilling | Milwaukee, WI | Vascular & Interventional Radiology | $8,027.63 |
| Matthew Johnson | Indianapolis, IN | Vascular & Interventional Radiology | $8,000.00 |
| Sanjeeva Kalva | Dallas, TX | Vascular & Interventional Radiology | $8,000.00 |
| Ziv Haskal | Charlottesville, VA | Vascular & Interventional Radiology | $8,000.00 |
Prescribed General - Interventional Oncology?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.